IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Birgit Bossenmaier et al. Application No.: 10/619,754 Filed: July 14, 2003 Title: METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES Art Unit: 1643 Attorney Docket: GNE-0114A Confirmation No. 3323 Customer No. 35489	In re Application)	Examiner: Holleran, Anne L.
Application No.: 10/619,754 Application No.: 10/619,754 Filed: July 14, 2003 Title: METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT Art Unit: 1643 Attorney Docket: GNE-0114A Confirmation No. 3323 Customer No. 35489)	
Application No.: 10/619,754) Attorney Docket: GNE-0114A Filed: July 14, 2003) Confirmation No. 3323 Title: METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT) Customer No. 35489	Inventor(s): Birgit Bossenmaier et al.)	
) Attorney Docket: GNE-0114A Filed: July 14, 2003) Confirmation No. 3323 Title: METHODS FOR IDENTIFYING TUMORS) THAT ARE RESPONSIVE TO TREATMENT) Customer No. 35489)	Art Unit: 1643
Filed: July 14, 2003 Confirmation No. 3323 Title: METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT Customer No. 35489	Application No.: 10/619,754)	
Title: METHODS FOR IDENTIFYING TUMORS) THAT ARE RESPONSIVE TO TREATMENT) Confirmation No. 3323 Customer No. 35489)	Attorney Docket: GNE-0114A
Title: METHODS FOR IDENTIFYING TUMORS) THAT ARE RESPONSIVE TO TREATMENT) Customer No. 35489	Filed: July 14, 2003)	
THAT ARE RESPONSIVE TO TREATMENT) Customer No. 35489)	Confirmation No. 3323
<i>'</i>)	G 37 47100
WITH ANTI-ErbB2 ANTIBODIES))	Customer No. 35489
	WITH ANTI-ErbB2 ANTIBODIES)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

	This sta	is statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):		
		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR	
		(2)	It is being filed within 3 months of entry of a national stage OR	
		(3)	It is being filed before the mail date of the first Office Action on the merits OR	
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.	
	37 C.F.R. $\S1.97(c)$. If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage set forth in $\S1.491$ in an international application; or (3) the mailing date of a first Office action on merits, but before the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$, then:			
		a certif	rication as specified in §1.97(e) is provided below; or	
			f \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the nt of other papers filed together with this statement.	
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final of action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, t			
	A.	a certif	ication as specified in §1.97(e) is completed below; and	
	В.	a petition herewit	on under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted th; and	
	C.		f $$130.00$ as set forth in $$1.17(i)(1)$ is authorized below, enclosed, or included with the nt of other papers filed together with this statement.	
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees \$0.00 and charge any additional fees or credit any overpayment associated with this communicat Deposit Account No. 50-4634 (Docket No. GNE-0114A (123851-181770)).			
			Respectfully submitted, GOODWIN PROCTER LLP	
Dated:	Novem	ber 13, 2	By Electronic Signature: /GINGER R. DREGER/ Ginger Dreger, Reg. No. 33,055	

Goodwin|Procter LLP 135 Commonwealth Drive Menlo Park, CA 94025 (650) 752-3100 Customer No. 35489